DANVILLE, Calif.–(BUSINESS WIRE)–BryoLogyx Inc., (www.BryoLogyx.com),
a privately-held, pre-clinical company developing a new class of
proprietary drugs to enhance the response rates and treatment durability
of cancer immunotherapies, announced today that the Company has named
William Grossman, M.D., Ph.D., to its Board of Directors. Dr. Grossman
has had a distinguished career in oncology research leadership in
industry, including at Genentech/Roche, AbbVie, Merck, as well as at
several biotechnology companies.
“Dr. Grossman’s appointment occurs as we put in place the foundation for
clinical development of our bryostatin-1 lead compound,” said Thomas
Loarie, Co-Founder and CEO of BryoLogyx. “Dr. Grossman brings an
extraordinary record of clinical accomplishment and cancer drug
development and research leadership. We look forward to his guidance as
we advance bryostatin-1 as a promising complement to cancer
immunotherapies.”
Dr. Grossman joins BryoLogyx following his recent appointment as Chief
Medical Officer at Arcus Biosciences. Prior to this appointment, Dr.
Grossman served as the Chief Medical Officer at Bellicum
Pharmaceuticals, a cellular-based therapy company. Dr. Grossman has held
several other global oncology leadership positions including Group
Development Team Lead for cancer immunotherapy combinations in solid
tumors and late-stage GI at Genentech/Roche, the US and Global Medical
Affairs Head of Oncology at AbbVie, as well as positions at Baxter
Healthcare Corporation, Merck & Co., and Biothera Inc.
Dr. Grossman’s career in the pharmaceutical industry followed his tenure
in clinical and academic medicine, specializing in cancer treatment and
immunology. Previously, he had served as Associate Professor at
Children’s Hospital of Wisconsin and the Medical College of Wisconsin in
the Hematology/Oncology & Blood and Marrow Transplant Program, where he
performed research in human immunology and was the Founder and Medical
Director of the Clinical Immunodiagnostic and Research Laboratory and
Immunodeficiency Program. Dr. Grossman earned his M.D. and Ph.D.
(Immunology) degrees from the Washington University School of Medicine.
“It is a privilege to join the world class management and scientific
teams at BryoLogyx. The company is poised to advance bryostatin at a
time when the industry can be optimistic about bringing forward numerous
therapeutics for manipulating the immune system to fight cancer,” said
Dr. Grossman. “BryoLogyx has a vision to substantially benefit the
survival of cancer patients, building on bryostatin research at the
National Cancer Institute. I look forward to helping bring that vision
to medical and commercial success.”
About BryoLogyx
BryoLogyx is developing a new class of drugs to enhance the response
rates and treatment durability of cancer immunotherapies and anti-HIV
agents. The company’s initial focus is on cancer, where it is
capitalizing on two recent scientific advances: the discovery that a
complex natural product, bryostatin, stimulates tumor antigen production
to amplify the immune response unleashed by cancer immunotherapy; and
the invention of the first practical synthetic production method for
bryostatin and analogs, enabling their availability for commercial
development and use. BryoLogyx has exclusive rights from Stanford
University to the method’s use in the areas of cancer and HIV.
Bryostatin-1 is expected to enter Phase 1b clinical trials in 2020 to
study its potential role in enhancing immuno-oncology drugs in the
treatment of hematologic (blood) cancers. Learn more at www.bryologyx.com
Contacts
Peter Steinerman, Steinerman Biomedical Communications, prsteinerman@gmail.com